Travere Therapeutics is a biopharmaceutical company with a global team dedicated to working with the rare disease community to identify, develop, and deliver life-changing therapies. The Company’s development efforts are led by sparsentan, a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) – rare kidney disorders that often lead to end-stage kidney disease. The company is also advancing pegtibatinase (TVT-058) for the treatment of classical homocystinuria, a genetic metabolic disorder that can cause life-threatening thrombotic events. Travere Therapeutics’ early research efforts include partnering with leaders in patient advocacy and government research to identify potential therapeutics for Alagille syndrome,. The Company also delivers the FDA-approved therapies, Chenodal®, Cholbam®, Thiola®, and Thiola EC®, and is committed to ensuring broad access, educational, and financial support for patients. For more information, visit travere.com.

Travere Therapeutics was founded as Retrophin, Inc. in February 2011 and became public in December 2012. We adopted the name Travere Therapeutics, Inc. on November 16, 2020.

Our fiscal year ends December 31.

Travere Therapeutics is listed on the NASDAQ Global Market with a ticker symbol of TVTX.

Travere Therapeutics is incorporated in Delaware.

Travere Therapeutics’ CUSIP number is 89422G107.

We are located at:
3611 Valley Centre Drive, Ste. 300
San Diego, CA 92130

We currently do not pay a dividend and do not offer a Dividend Reinvestment Plan.

Any investor inquiries regarding the transfer or exchange of Travere shares, lost stock certificates, duplicate mailings, change of name requests, change of ownership requests, or change of address requests should be directed to the Transfer Agent:

American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
Toll free: +1 800-937-5449
Outside the United States: +1 718-921-8124
TDD/TTY: +1 866-703-9077 (within the United States) or +1 718-921-8386 (outside the United States)
E-mail: info@amstock.com
Website: www.astfinancial.com/

Any investor inquiries regarding the transfer or exchange of Travere shares, lost stock certificates, duplicate mailings, change of name requests, change of ownership requests, or change of address requests should be directed to the Transfer Agent:
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
Toll free: +1 800-937-5449
Outside the United States: +1 718-921-8124
TDD/TTY: +1 866-703-9077 (within the United States) or +1 718-921-8386 (outside the United States)
E-mail: info@amstock.com
Website: www.astfinancial.com/ 

To change your address, please contact the transfer agent.

Travere Therapeutics’ independent auditor is BDO USA, LLP.

View publications here or at SEC.gov. Also see press releases. 

At Travere, we recognize the importance of ESG. While we have not yet adopted a comprehensive ESG reporting system, we have a number of activities and initiatives that align with ESG goals, including, among others: corporate goals and initiatives in furtherance of an inclusive culture and the attraction and retention of diverse talent, the operation of an internal diversity council, providing comprehensive wellness support for employees, supporting access and education for the rare disease community, and the incorporation of ESG initiatives as part of our overall Enterprise Risk Management program. We encourage you to visit the Who We Are page to learn more about our mission, values, and vision, and the initiatives we are committed to supporting.

Please also visit Travere Therapeutics’ Patient Advocacy page to learn more about our involvement in changing the rare disease healthcare system and building a world where every patient is treated fairly and equally.

For patient inquiries, please contact the Travere Call Center at +1 877-659-5518 or via e-mail at medinfo@travere.com.
To report suspected adverse reactions, contact Travere Therapeutics at +1 877-659-5518, or contact the FDA at +1 800-FDA-1088 or www.fda.gov/medwatch.
If you are a member of the media, please contact mediarelations@travere.com or +1 888-969-7879. For additional information you may also visit the Press Releases section of our website.
If you would like to submit business development inquiries, please contact us at partnering@travere.com. 
Any investor-related inquiries not handled by the Transfer Agent should be directed to ir@travere.com.
All other inquiries may be submitted via the Contact Us form or by calling +1 888-969-7879.  Any personal information you provide us will be processed according to our Privacy Policies.